Promoted Content
Promoted Content

Find Oncology Drugs in Phase III Clinical Development in SWITZERLAND

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
News Type filter
    Company filter
      Product Type filter
        Deal Size filter
          Upfront Payment filter
            refresh

            Product Type Full Screen

            Companies Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Galinpepimut-S

            Therapeutic Area: Oncology Product Name: SLS-001

            Highest Development Status: Phase III Product Type: Vaccine

            Partner/Sponsor/Collaborator: 3D Medicines

            Deal Size: $202.0 million Upfront Cash: $7.5 million

            Deal Type: Licensing Agreement December 07, 2020

            Details:

            3DMed gets rights to develop and market SELLAS’ lead late-stage clinical candidate, galinpepimut-S, as and its next generation heptavalent immunotherapeuatic, GPS+ across all therapeutic and diagnostic uses in the Greater China territory.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Nadofaragene firadenovec

            Therapeutic Area: Oncology Product Name: rAd-IFN/Syn3

            Highest Development Status: Phase III Product Type: Cell and Gene therapy

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable November 30, 2020

            Details:

            Novel rAd-IFN/Syn3 intravesical gene therapy given once every three months studied in patients with high-grade, BCG-unresponsive non-muscle invasive bladder cancer.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Asciminib

            Therapeutic Area: Oncology Product Name: ABL001

            Highest Development Status: Phase III Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable November 19, 2020

            Details:

            Company to present data on Pivotal ASCEMBL study of novel, investigational STAMP inhibitor asciminib (ABL001) vs. bosutinib in CML patients previously treated with two or more TKIs, ELARA results for Kymriah® in r/r follicular lymphoma, long-term JULIET data including others.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Ribociclib,Tamoxifen,Goserelin Acetate

            Therapeutic Area: Oncology Product Name: Kisqali

            Highest Development Status: Phase III Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable November 02, 2020

            Details:

            KISQALI® is the first CDK4/6 inhibitor to show statistically significant improvement in overall survival (key secondary endpoint) in advanced breast cancer in pre- and perimenopausal women.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Balixafortide,Eribulin Mesylate

            Therapeutic Area: Oncology Product Name: POL6326

            Highest Development Status: Phase III Product Type: Peptide

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable October 29, 2020

            Details:

            The FORTRESS study is an international, multicenter, randomized active-controlled, open-label Phase III trial which investigates the efficacy, safety and tolerability of intravenous balixafortide given with eribulin vs eribulin alone to treat metastatic breast cancer.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Xevinapant,Cisplatin,Radiotherapy

            Therapeutic Area: Oncology Product Name: Debio 1143

            Highest Development Status: Phase III Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable October 01, 2020

            Details:

            The clinical trial is being conducted to demonstrate the superior efficacy of xevinapant vs. placebo when added to CRT in high risk head and neck patients including those affected in the throat and vocal chords (oropharynx -HPV-negative, hypopharynx and larynx).

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Ribociclib,Tamoxifen,Letrozole

            Therapeutic Area: Oncology Product Name: Kisqali

            Highest Development Status: Phase III Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable September 21, 2020

            Details:

            Kisqali is the only CDK4/6 inhibitor, in combination with endocrine therapy, to achieve a perfect 5 out of 5 score, confirming substantial benefit for premenopausal women with HR+/HER2- advanced breast cancer, based on strong overall survival benefit in the MONALEESA-7 trial.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Xevinapant,Cisplatin,Radiotherapy

            Therapeutic Area: Oncology Product Name: Debio 1143

            Highest Development Status: Phase III Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable September 17, 2020

            Details:

            The virtual late breaking abstract presentation of the 3-year update for the xevinapant phase II study in high-risk previously untreated locally advanced squamous cell carcinoma of the head and neck (LA-SCCHN) patients, will be Presented at ESMO Virtual Congress 2020.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Asciminib

            Therapeutic Area: Oncology Product Name: ABL001

            Highest Development Status: Phase III Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable August 26, 2020

            Details:

            At primary analysis, ASCEMBL met its primary endpoint of significant superiority in major molecular response rate at 24 weeks for asciminib (ABL001) vs. bosutinib in patients previously treated with two or more tyrosine-kinase inhibitors (TKIs).

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Spartalizumab,Dabrafenib,Trametinib

            Therapeutic Area: Oncology Product Name: PDR001

            Highest Development Status: Phase III Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable August 22, 2020

            Details:

            Phase III COMBI-i trial did not meet primary endpoint for patients with advanced BRAF V600-mutated melanoma.

            PharmaCompass